Vanda Pharmaceuticals acquires U.S. and Canadian rights to PONVORY

Vanda Pharmaceuticals (VNDA) announced that it has acquired U.S. and Canadian rights to PONVORY from Actelion Pharmaceuticals, a Johnson & Johnson (JNJ) company. PONVORY is approved by the U.S. FDA and Health Canada to treat adults with relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease. PONVORY has a proven safety profile with over 10 years of data.